Skip to Main Content

User Profile

AGLN - Aspen Global Leadership Network
  • About AGLN
    Mission, Approach, Impact Leadership and Team AGLN Moderators Blog
  • Fellowships
    ABOUT
    AGLN Fellowships Becoming a Fellow Lifelong Engagement Search the AGLN Directory
    US-BASED FELLOWSHIPS
    Civil Society Fellowship Health Innovators Fellowship Henry Crown Fellowship Liberty Fellowship Pahara Fellowship
    GLOBAL FELLOWSHIPS
    Africa Leadership Initiative - East Africa Africa Leadership Initiative - South Africa Africa Leadership Initiative - West Africa Finance Leaders Fellowship Central America Leadership Initiative China Fellowship Program Kamalnayan Bajaj Fellowship Middle East Leadership Initiative
  • Ventures
  • Action Forum
    About Register Previous Action Forums 2024 Action Forum Recap Youth Action Forum Partners & Supporters
  • Login
Kevin Judice
Kevin Judice

Kevin Judice

Connect on Social Media

[Edit]

LinkedIn:
https://www.linkedin.com/in/kevin-judice-ba18016
Twitter:
https://twitter.com/KevinJudice

About

[Edit]

First Name:
Kevin
Last Name:
Judice
Title and Organization:
Chief Executive Officer, DiCE Molecules
Bio:
Kevin Judice currently serves as chief executive officer of DiCE Molecules. Prior to this he founded K2 Therapeutics and was CEO and Chief Scientific Officer of Achaogen, Inc., a biopharmaceutical company that he co-founded to develop novel antibiotics for the treatment of life-threatening infections. In addition to setting corporate strategy and building the leadership team as President and CEO, Kevin also served as the company's Chief Scientific Officer. In this role, he was responsible for the overall scientific strategy, research priorities, and portfolio management. Along with its commercial efforts, Achaogen is engaged in several collaborations with the federal government to develop bio-terrorism countermeasures. Previously, Kevin held positions of increasing responsibility at Genentech and Theravance. As one of the first ten employees at Theravance, he played a key role in defining the company's scientific strategies and led the team that discovered telavancin, a new antibiotic for the treatment of multidrug-resistant "superbugs". Kevin graduated magna cum laude with a BS in Chemistry from Texas A&M University. Following that, he received his Ph.D. in Organic Chemistry from UCLA and was an NIH postdoctoral fellow at UC Berkeley. He is an author and inventor on over two dozen scientific papers and patents. Kevin is a member of the 2008 class of Henry Crown Fellows at the Aspen Institute and a member of the Aspen Global Leadership Network.

Fellowship Program

[Edit]

Program Membership:
Henry Crown Fellowship Program

Class

[Edit]

Fellowship Class Name:
Class XII: 2008 Twelfth Knights Class


© The Aspen Institute | Privacy Policy | Terms of Use | Powered by Personify Community
Facebook Twitter YouTube Instagram

You are here because you are logging into the AGLN community website for the first time or you forgot your password.

 

Please enter the email address associated with your account and a new password will be sent to you. If you are still having issues logging in or do not have access to the email that the Aspen Global Leadership Network uses to contact you, please email agln.info@aspeninstitute.org to have your password manually reset and sent to you.